The safety and efficacy of intravenous thrombolysis for ischemic stroke in an elderly patient with thrombocytopenia: The safety and efficacy of intravenous thrombolysis for ischemic stroke

Ricky Candra Wijaya

doi:10.59747/smjidisurabaya.v1i1.10

Penulis

Ricky Candra Wijaya Emergency Department, Faculty of Medicine, Universitas Surabaya, Mitra Keluarga Hospital, Surabaya, Indonesia

DOI:

https://doi.org/10.59747/smjidisurabaya.v1i1.10

Kata Kunci:

hypertension, stroke, type 2 diabetes mellitus, rTPA

Abstrak

Background: Strokes remain as one of the diseases with high mortality and morbidity, which can be prevented through prompt and concise treatment. Intravenous thrombolysis (IV-rTPA) is the mainstay treatment for hyperacute ischemic stroke with onsets of less than 4.5 hours. However, it has several contraindications that should be monitored, one of them being thrombocytopenia. Objectives: This case report details the use of IV-rTPA in a geriatric patient with thrombocytopenia to highlight its efficacy and safety. Case: An 85-year-old woman was admitted to the emergency ward with weakness in the left extremities, slurred speech, and upward-right gaze one hour prior to ER admission. She had a significant history of hypertension and type II diabetes mellitus. A physical examination revealed a muscle strength of +5/+1, palsy in the left 7th and 12th cranial nerves, an NIHSS score of 15, and a RACE score of 7. The laboratory result was positive for thrombocytopenia (96,000/μl). IV-rTPA was administered, and two hours later, the patient's NIHSS score raised to 11. During the IV-RTPA administration, there was minor gum bleeding, which was considered insignificant. The patient was admitted to the ICU and observed for the next 72 hours. No signs of bleeding or clinical deterioration were observed during that period. Numerous studies have confirmed IV-rTPA's efficacy in acute ischemic stroke treatment if administered before 4.5 hours of onset. Thrombocytopenia is known as a contraindication of IV-rTPA, which may increase the risk of bleeding. In this case, IV-rTPA was administered due to hyperacute onset and no known history of bleeding despite low platelet count. Conclusion: IV-rTPA may be considered if the benefits outweigh the risks, coupled with thorough monitoring of the patient's condition.

Referensi

Brown, C., Terrell, K., Goodwin, R., Nathaniel, T., 2022. Stroke Severity in Ischemic Stroke Patients with a History of Diastolic Blood Pressure Treated in a Telestroke Network. J. Cardiovasc. Dev. Dis. 9(10): 345. doi: 10.3390/jcdd9100345.

Brunner, F., Tomandl, B., Schröter, A., Mellinghoff, C., Haldenwanger, A., Hildebrandt, H., Kastrup, A., 2011. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur. J. Neurol. 18(12):1407–1411. doi: 10.1111/j.1468-1331.2011.03455.x.

Chen, Chih Hao, Tang, S.C., Chen, Y.W., Chen, Chih Hung, Tsai, L.K., Sung, S.F., Lin, H.J., Huang, H.Y., Po, H.L., Sun, Y., Chen, P.L., Chan, L., Wei, C.Y., Lee, J.T., Hsieh, C.Y., Lin, Y.Y., Lien, L.M., Jeng, J.S., 2022. Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h. Front. Neurol. 13:763963. doi: 10.3389/fneur.2022.763963.

Chen, R., Ovbiagele, B., Feng, W., 2017. Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci. 351(4):380–386. doi: 10.1016/j.amjms.2016.01.011.

Frank, B., Grotta, J.C., Alexandrov, A. V., Bluhmki, E., Lyden, P., Meretoja, A., Mishra, N.K., Shuaib, A., Wahlgren, N.G., Weimar, C., Lees, K.R., 2013. Thrombolysis in stroke despite contraindications or warnings? Stroke 44(3):727–733. doi: 10.1161/STROKEAHA.112.674622.

Fugate, J.E., Rabinstein, A.A., 2015. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. The Neurohospitalist 5(3): 110–121. doi: 10.1177/1941874415578532.

Gensicke, H., Al Sultan, A.S., Strbian, D., Hametner, C., Zinkstok, S.M., Moulin, S., Bill, O., Zini, A., Padjen, V., Kägi, G., Pezzini, A., Seiffge, D.J., Traenka, C., Räty, S., Amiri, H., Zonneveld, T.P., Lachenmeier, R., Polymeris, A., Roos, Y.B., Gumbinger, C., Jovanovic, D.R., Curtze, S., Sibolt, G., Vandelli, L., Ringleb, P.A., Leys, D., Cordonnier, C., Michel, P., Lyrer, P.A., Peters, N., Tatlisumak, T., Nederkoorn, P.J., Engelter, S.T., 2018. Intravenous thrombolysis and platelet count. Neurology 90(8):e1–e8. doi: 10.1212/WNL.0000000000004982.

Godwin, K.M., Wasserman, J., Ostwald, S.K., 2011. Cost associated with stroke: Outpatient rehabilitative services and medication. Top. Stroke Rehabil. 18(Suppl 1):676–684. doi: 10.1310/tsr18s01-676.

Harada, S., Fujita-Hamabe, W., Tokuyama, S., 2012. Ischemic stroke and glucose intolerance: A review of the evidence and exploration of novel therapeutic targets. J. Pharmacol. Sci. 118(1):1–13. doi: 10.1254/jphs.11r04cr.

Huang, X., Nash, P., Alakbarzade, V., Clarke, B., Pereira, A.C., 2021. Clinical Outcomes after Intravenous Alteplase in Elderly Patients with Acute Ischaemic Stroke: A Retrospective Analysis of Patients Treated at a Tertiary Neurology Centre in England from 2013 to 2018. Stroke Res. Treat. 2021:3738017. doi: 10.1155/2021/3738017.

Krishnamurthi, R. V., Ikeda, T., Feigin, V.L., 2020. Global, Regional and Country-Specific Burden of Ischaemic Stroke, Intracerebral Haemorrhage and Subarachnoid Haemorrhage: A Systematic Analysis of the Global Burden of Disease Study 2017. Neuroepidemiology 54(2):171–179. doi: 10.1159/000506396.

Martini, S.R., Kent, T.A., 2007. Hyperglycemia in acute ischemic stroke: A vascular perspective. J. Cereb. Blood Flow Metab. 27(3):435–451. doi: 10.1038/sj.jcbfm.9600355.

Meretoja, A., Putaala, J., Tatlisumak, T., Atula, S., Artto, V., Curtze, S., Häppölä, O., Lindsberg, P.J., Mustanoja, S., Piironen, K., Pitkäniemi, J., Rantanen, K., Sairanen, T., Salonen, O., Silvennoinen, H., Soinne, L., Strbian, D., Tiainen, M., Kaste, M., 2010. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 41(7):1450–1458. doi: 10.1161/STROKEAHA.109.576140.

Micieli, G., Marcheselli, S., Tosi, P.A., 2009. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc. Health Risk Manag. 5(1):397–409. doi: 10.2147/vhrm.s4561.

Mowla, A., Kamal, H., Lail, N.S., Vaughn, C., Shirani, P., Mehla, S., Rajabzadeh-Oghaz, H., Deline, C., Ching, M., Crumlish, A., Sawyer, R.N., 2017. Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Thrombocytopenia. J. Stroke Cerebrovasc. Dis. 26(7):1414–1418. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.021.

Powers, W.J., Rabinstein, A.A., Ackerson, T., Adeoye, O.M., Bambakidis, N.C., Becker, K., Biller, J., Brown, M., Demaerschalk, B.M., Hoh, B., Jauch, E.C., Kidwell, C.S., Leslie-Mazwi, T.M., Ovbiagele, B., Scott, P.A., Sheth, K.N., Southerland, A.M., Summers, D. V., Tirschwell, D.L., 2019. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke. 50(12):e344-e418. doi: 10.1161/STR.0000000000000211.

Qureshi, A.I., 2008. Acute hypertensive response in patients with stroke pathophysiology and management. Circulation 118(2):176–187. doi: 10.1161/CIRCULATIONAHA.107.723874.

Saposnik, G., Young, B., Silver, B., Di Legge, S., Webster, F., Beletsky, V., Jain, V., Nilanont, Y., Hachinski, V., 2004. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: Predictors and association with outcome. Jama 292(15):1839–1844. doi: 10.1001/jama.292.15.1839.

Saver, J.L., 2006. Time is brain - Quantified. Stroke 37(1):263–266. doi: 10.1161/01.STR.0000196957.55928.ab.

Sharma, S., Goyal, S., 2020. Study of Association of Platelet Indices With Acute Ischemic Stroke in Patients With Type 2 Diabetes Mellitus – a Hospital Based Study. Paripex Indian J. Res.9(3):1–3. doi: 10.36106/paripex.

Strozyk, D., Ocava, L.C., 2008. Stroke prevention: Update on antiplatelet therapy. Consultant 48(3):250–255.

Tun, N.N., Arunagirinathan, G., Sunil K Munshi, Joseph M Pappachan, 2017. Diabetes mellitus and stroke: A clinical update. World J. Diabetes 8(6):235–248. doi: 10.4239/wjd.v8.i6.235.

Wajngarten, M., Silva, G.S., 2019. Hypertension and Stroke : Update on Treatment. Radcliffe Cardiol. 14(2):111–115. doi: 10.15420/ecr.2019.11.1

Wang, Y.-R., Yang, L.-Y., Lee, C.-H., Chang, S.-H., Chen, P.-H., Jhou, H.-J., 2023. Is Thrombocytopenia an In-Hospital Mortality Risk Factor among Patients with Acute Ischemic Stroke? A Propensity Score-Matched Analysis from the MIMIC-IV Database. J. Clin. Med. 12(2):580. doi: 10.3390/jcm12020580.

Weiss, A., Beloosesky, Y., Kenett, R.S., Grossman, E., 2016. Change in systolic blood pressure during stroke, functional status, and long-term mortality in an elderly population. Am. J. Hypertens. 29(4):432–438. doi: 10.1093/ajh/hpv118.

Yang, M., Pan, Y., Li, Z., Yan, H., Zhao, X., Liu, L., Jing, J., Meng, X., Wang, Yilong, Wang, Yongjun, 2019. Platelet count predicts adverse clinical outcomes after ischemic stroke or TIA: Subgroup analysis of CNSR II. Front. Neurol. 10:370. doi: 10.3389/fneur.2019.00370.

The safety and efficacy of intravenous thrombolysis for ischemic stroke in an elderly patient with thrombocytopenia